|1.||Kumar, Piyush: 4 articles (07/2015 - 04/2003)|
|2.||Wiebe, Leonard Irving: 2 articles (03/2015 - 04/2003)|
|3.||Wiebe, Leonard I: 2 articles (06/2013 - 08/2005)|
|4.||McEwan, Alexander J B: 2 articles (06/2013 - 08/2005)|
|5.||Mercer, J R: 2 articles (09/2001 - 01/2000)|
|6.||Wiebe, L I: 2 articles (09/2001 - 01/2000)|
|7.||McEwan, A J: 2 articles (09/2001 - 01/2000)|
|8.||Narain, Ravin: 1 article (07/2015)|
|9.||Wang, Yinan: 1 article (07/2015)|
|10.||Quan, Stephen: 1 article (07/2015)|
06/06/2013 - "In order to modulate the clearance of bound and free radioactive IAZA, nonradioactive (cold) IAZA was administered i.v. 1 h following injection of high specific activity [125I][IAZA in the Balb/C EMT-6 murine tumor model. "
06/06/2013 - "[131I]IAZA as a molecular radiotherapeutic (MRT) drug: wash-out with cold IAZA accelerates clearance in a murine tumor model."
08/01/2005 - "Based on measured radioactivity burdens during the week following injection and on published animal ([(125)I]IAZA) and clinical ([(123)I]IAZA) dosimetry data, the current dose estimates point to selective tumor irradiation at low dose rates."
08/01/2005 - "IAZA cytotoxicity (IC(50), approximately 0.1 mM) against both murine (EMT-6) and human (143B, 143B-LTK) tumor cells determined by MTT test was in the range previously reported for EMT-6 cells using a clonogenic assay. "
01/01/2000 - "Three proposed metabolites of IAZA--methyl 5-deoxy-5-iodo-D-arabinofuranoside, methyl 2,3-di-O-acetyl-5-deoxy-5-iodo-alpha-D-arabinofuranoside, and 1-(5-deoxy-5-iodo-alpha-D-arabinofuranosyl)-2-aminoimidazole (IAIA)--were synthesized, radiolabeled with 125I, and investigated in normal and tumor-bearing murine models for their contribution to this unusual phenomenon. "
04/01/2003 - "Radioiodinated IAZA ((123)I-IAZA) has been extensively studied as a radiopharmaceutical for the diagnosis of regional and/or focal tissue hypoxia in a variety of clinical pathologies. "
04/01/2003 - "Synthesis of 1-beta-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (beta-IAZA): a novel marker of tissue hypoxia."
06/01/1999 - "123I-labelled iodoazomycin arabinoside (123I-IAZA) is an experimental radiopharmaceutical that has been shown to have clinical utility for imaging regional tissue hypoxia. "
07/01/1996 - "Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside."
09/01/1991 - "Radioiodinated IAZA was shown to undergo hypoxia-dependent binding in EMT-6 cells in vitro and to have an initial binding rate of 284 pmole/10(6) cells/hr at a substrate concentration of 30 microM. "
|3.||Lung Neoplasms (Lung Cancer)
|4.||Peripheral Vascular Diseases (Peripheral Vascular Disease)
12/01/1994 - "We have evaluated a new, radiolabelled, in vivo marker of tissue hypoxia, iodoazomycinarabinoside (IAZA), by comparing TcpO2 measurements with patterns of iodine-123 IAZA uptake in ten patients (19 lower limbs) with DM and peripheral vascular disease using conventional gamma camera imaging techniques. "
|5.||Neoplasm Metastasis (Metastasis)
|2.||Gamma Cameras (Gamma Camera)